title: Nasal septal perforation from bevacizumab: a discussion of outcomes, management, and pharmacovigilance.
abstract: To date, the published literature describes 18 reports of nasal septal perforation in cancer patients with the administration of bevacizumab. This complication was detected during post-marketing surveillance of bevacizumab. How should patients who develop this complication be managed? This discussion summarizes suggestions for management of bevacizumab-associated nasal septal perforation and, as relevant to healthcare providers, discusses some of the practical aspects of post-marketing pharmacovigilance.
authors.affiliation: Mayo Clinic Medical School, Rochester, MN, USA.
authors.forename: Judi Anne B
authors.initials: JA
authors.lastname: Ramiscal
authors.forename: Aminah
authors.initials: A
authors.lastname: Jatoi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068258:Bevacizumab; D006801:Humans; D061270:Nasal Septal Perforation / Q000139:chemically induced*; D060735:Pharmacovigilance
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab